Creative Medical Technology Holdings, Inc. (CELZ): רווח נקי למניה (EPS TTM)

The development of Creative Medical Technology (CELZ) relies on internal innovation cycles and the success of clinical trials, which minimizes macroeconomic influence. The 12-month EPS trend demonstrates financial stability, with the value holding at -1.71. Creative Medical Technology (CELZ) is based on the work of a tight-knit circle of scientists, while its growth is constrained by strict ethical oversight and complex licensing for cellular technologies.

Net income per share reflects the actual return on each unit of capital over the last twelve months. By analyzing the rolling trailing twelve-month earnings per share, an investor sees the result of dividing total net income by the total number of issued securities. Growth in this metric confirms the efficiency of resource management. For Creative Medical Technology (CELZ), negative values are expected, as the company invests raised funds into costly clinical trials of stem cells.